Epstein Secrets

srs. Dorsey, McKelvey. Khosla, and Johnson and Drs. Summers and Simmons were elected as the designees nominated by holders of our common stock; Mr. Botha was elected as the designee nominated by holders of our Series B convertible preferred stock; • Ms. Meeker was elected as the designee nominated by

-year terms. Our current directors will be divided among the three classes as follows: • the Class I directors will be Messrs. Dorsey, Johnson, and Viniar, and their terms will expire at the annual meeting of stockholders to be held in 2016: • the Class II directors will be Messrs. Botha and McKelvey

B convertible preferred stock; • Ms. Meeker was elected as the designee nominated by holders of our Series C convertible preferred stock; and • Mr. Viniar was elected as a designee nominated by holders of a majority of each of our common stock and our convertible preferred stock. In connection with th

resignation or until otherwise determined by our board of directors. Audit and Risk Committee Our audit and risk committee is comprised of Messrs. Botha and Viniar and Dr. Summers, each of whom satisfies the requirements for independence and financial literacy under the applicable rules and regulatio

York Stock Exchange, our board of directors has appointed David Viniar to serve as our Lead Independent Director. As Lead Independent Director, Mr. Viniar will preside over periodic meetings of our independent directors, serve as a liaison between our Chairman and our independent directors, and perfor

S- I/A serving on our board of directors or compensation committee. Ms. Meeker, a General Partner of Kleiner Perkins Caufield & Byers, and Mr. Botha. a Managing Member of Sequoia Capital, comprise our compensation committee. Entities affiliated with Kleiner Perkins Caufield & Byers and entities a

mmers' continued service with us. As of December 31, 2014, Dr. Summers held 161,000 restricted shares of our common stock. On October 30, 2013, Mr. Viniar was granted an option to purchase 326,950 shares of our common stock. This option is early exercisable. One-fourth of the shares subject to the opti